NovaMedica is in advanced negotiations to secure Russia and CIS rights for a wide range of innovative Products. We are seeking specialty pharmaceutical drugs and devices from various potential US and European partners (including Domain Associates, Inc. portfolio companies) spanning several high-growth therapeutic areas in hospital inpatient, hospital outpatient and specialty care clinical contexts. Products can be both FDA/EMA approved and phase 2B/3 late-stage development. Please check back regularly as we grow our pipeline to serve this exciting market.
October 10 – World Mental Health Day
10 October 2024
Long-Term Game: NovaMedica Experts at the Pharma Marketing Conference
10 October 2024
NovaMedica in the TOP-1000 Russian Managers Rating
28 September 2024
Federal Center for Animal Health develops 13 new veterinary vaccines
22 October 2024
Haemophilia treatment with new delivery method approved
22 October 2024
Immunotherapy treatment enhances lymphoma survival, landmark study shows
21 October 2024
The Russian Ministry of Health initiates the creation of a list of key drugs
21 October 2024